PRESS RELEASE published on 07/11/2024 at 18:45, 1 year 4 months ago Theranexus publishes its cash position as of 30 June 2024 and presents an update on the progress of Batten-1 Biopharmaceutical company Theranexus announces implementation of new equity line to finance Phase III trial for Batten-1 drug in juvenile Batten disease. Update on Batten-1 program included Biopharmaceutical Company Phase III Trial Theranexus Batten-1 Equity Line
BRIEF published on 07/03/2024 at 07:35, 1 year 5 months ago Theranexus, CRNL and CERMEP winners of the Auvergne-Rhône-Alpes “Research Pact 2024” project Research Neurology Auvergne-Rhône-Alpes Theranexus Neuroimaging
PRESS RELEASE published on 07/03/2024 at 07:30, 1 year 5 months ago THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP WIN THE "2024 RESEARCH PACT" PROJECT FOR THE AUVERGNE-RHÔNE-ALPES REGION Theranexus, Lyon Neuroscience Research Center, and CERMEP win research pact project 'IMASO' in Auvergne-Rhône-Alpes Region for preclinical neuroimaging in rare neurological diseases Theranexus Neurological Diseases Research Pact Auvergne-Rhône-Alpes Region Preclinical Neuroimaging
BRIEF published on 06/06/2024 at 07:35, 1 year 5 months ago Theranexus and BBDF Announce Positive Results at 18 Months for Batten-1 in Phase 1/2 Study Theranexus Batten-1 BBDF Batten Disease Neurofilaments
PRESS RELEASE published on 06/06/2024 at 07:30, 1 year 5 months ago Theranexus and BBDF confirm positive 18-month results for Batten-1 in Phase I/II trial based on neurofilaments, a biomarker of neuronal death Theranexus and BBDF confirm positive results in Phase I/II trial evaluating Batten-1 drug for CLN3 Batten disease after 18 months of treatment, showing decline in NfL biomarker levels and therapeutic potential Theranexus Batten-1 BBDF CLN3 Batten Disease Neurofilament Light Chains
BRIEF published on 05/02/2024 at 07:35, 1 year 7 months ago Theranexus unveils its universal registration document for 2023 2023 Biopharmaceutical Universal Registration Document Theranexus Rare Neurological Diseases
BRIEF published on 04/29/2024 at 18:25, 1 year 7 months ago Theranexus Reports 2023 Full-Year Results and Details Recent Progress 2023 Financial Results Theranexus Rare Neurological Diseases PickASO Project Batten Disease
PRESS RELEASE published on 04/29/2024 at 18:20, 1 year 7 months ago THERANEXUS PUBLISHES ITS 2023 FULL-YEAR RESULTS AND PRESENTS ITS PROGRESS REPORT Theranexus reports 2023 financial results, cash position, progress report, and the arrival of Christine Placet as CFO. Highlights include positive Batten-1 trial results and funding options for future trials Financial Results Theranexus Rare Neurological Diseases Christine Placet Batten-1 Trial
BRIEF published on 04/29/2024 at 18:05, 1 year 7 months ago Theranexus announces its 2023 annual results and the progress of its projects Biotechnology 2023 Financial Results Rare Diseases Theranexus Research Phase
BRIEF published on 04/26/2024 at 18:05, 1 year 7 months ago Theranexus releases voting rights and capital information for March 2024 Share Capital Voting Rights Biopharmaceutical Neurology Theranexus
Published on 12/05/2025 at 02:35, 10 hours 39 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 12 hours 14 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 9 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 14 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 13:00, 14 minutes ago Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 14 minutes ago Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 9 minutes ago Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 14 minutes ago CGTN:Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 1 hour 14 minutes ago Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million
Published on 12/05/2025 at 08:45, 4 hours 29 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 19 hours 14 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 19 hours 29 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 19 hours 30 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 6 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health